Electricogenetics: Precision Genetics for Neuromodulation Success
Empowering doctors and patients with genetic insights that transform mental health care.
Request a Test Kit (comming Soon)
We combine your genetic data with your real time physiologic response to improve outcomes.
Eletroceurticals don't work the same for everyone — and we finally know why. Our revolutionary approach to neuromodulation therapy is changing how doctors approach treatment-resistant conditions.
Genetic Precision
Our NeuroResponse™ Genetic Panel identifies the specific neurochemical and neuroplastic traits that predict treatment efficacy before you invest valuable clinical resources.
Personalized Protocols
Tailor stimulation parameters, frequency, and duration based on your patient's unique genetic profile, dramatically improving response rates.
Evidence-Based Decisions
Replace guesswork with data-driven protocols that address the specific neurobiological factors affecting your patients' treatment outcomes.
By incorporating genetic testing into your clinical workflow, you can predict which neuromodulation approach will work best for each patient before they sit in the treatment chair.
The Risk of Flying Blind
Without genetic insight, neuromodulation becomes an expensive game of chance. Patients invest weeks of time, thousands of dollars, and immeasurable hope into treatments that may be fundamentally mismatched to their neurogenetic profile.
Wasted Treatment Cycles
Patients may endure weeks of ineffective TMS sessions due to poor BDNF-mediated neuroplasticity or inflammatory resistance, delaying appropriate care while symptoms persist.
Medication Mismatches
Side effects and emotional blunting often result from medications mismatched to serotonin transporter genes (e.g., SLC6A4), leading to treatment abandonment and clinical frustration.
VNS Failure
Patients with low dopaminergic tone (e.g., DRD2 variants) may show minimal response to Vagus Nerve Stimulation despite significant investment in the intervention.
Unaddressed Metabolic Issues
Persistent fatigue and cognitive fog often stem from undiagnosed methylation issues (e.g., MTHFR C677T) that compromise neurotransmitter synthesis and neuroplasticity.
In today's precision medicine landscape, genetics isn't optional — it's essential. The cost of genetic testing is minimal compared to the financial and emotional expense of ineffective treatment cycles.
TMS: Targeting the Right Brain, Backed by the Right Genes
Transcranial Magnetic Stimulation works by activating underactive cortical regions, but its success relies on the brain's ability to remodel and learn — a process heavily influenced by genetic factors that vary significantly between patients.
Critical Genetic Markers We Test
  • BDNF Val66Met — determines the brain's capacity to adapt to TMS stimulation and form new neural connections
  • COMT Val158Met — affects dopamine tone, executive function, and cognitive control during treatment
  • MTHFR variants — low methylation capacity may impair neurotransmitter availability during stimulation
  • Inflammatory markers — genetic predisposition to neuroinflammation can blunt TMS efficacy
Clinical Implications
Patients with BDNF Met alleles typically require higher frequency or longer duration TMS protocols to achieve the same neuroplastic effects as Val/Val carriers.
Those with COMT Met/Met genotypes may be more emotionally sensitive to overstimulation and benefit from more gradual protocol adjustments.
Without this genetic data, TMS programming becomes expensive guesswork, often leading to suboptimal outcomes and patient attrition.
"Knowing my patient's BDNF status changed everything about how I approach TMS protocol selection. What used to be trial and error is now precision medicine." — ()
VNS: Not All Brains Respond the Same
Vagus Nerve Stimulation relies on modulating parasympathetic tone and deep limbic structures, including those involved in emotional regulation, memory, and inflammation. The genetic factors governing these systems create significant variability in treatment response.
1
Genetic Assessment
We analyze key genetic markers including DRD2 Taq1A (dopamine receptor density), IL-6 (-174G/C) inflammatory status, and SLC6A4 (5-HTTLPR) serotonin transport efficiency.
Response Prediction
Our algorithm generates a VNS Response Probability Score based on these genetic factors and their known interactions with vagal stimulation pathways.
Protocol Optimization
Clinicians receive specific recommendations for stimulation parameters, complementary interventions, and monitoring protocols based on the genetic profile.
Patients with high inflammatory risk (IL-6 C/C) or low dopaminergic drive (DRD2 A1/A1) may require additional support or may not respond to VNS at all. Others with ideal genetic profiles may be exceptional candidates. Our panel helps clarify the path before invasive intervention.
"We've reduced our VNS non-responder rate by 68% since implementing Electricogenetics testing as standard protocol." — Advanced Neuromodulation Center, Boston
A Lab Test That Works in the Real World
We designed our testing protocol to integrate seamlessly into your clinical workflow, with minimal disruption and maximum clinical utility. From collection to clinical implementation, our system prioritizes efficiency and actionable insights.
Simple Collection Process
  • Non-invasive buccal swab or standard whole blood collection options
  • Pre-labeled collection kits with clear patient instructions
  • Prepaid shipping materials included with every kit
  • Online portal for easy test registration and tracking
Rapid, Reliable Results
  • CLIA-certified laboratory processing
  • Results returned in 7–10 business days
  • HIPAA-compliant digital delivery system
  • Optional integration with major EHR platforms
Comprehensive Reporting
Each report includes detailed genetic findings, clinical interpretations, and specific treatment recommendations tailored to your patient's profile.
Patient Communication Tools
Patient-friendly explanations and visual aids help you communicate complex genetic information in accessible terms.
Protocol Integration
Specific recommendations for RTM programming, methylation support, and comprehensive care planning based on genetic findings.
Ideal For Specialized Clinical Needs
Our NeuroResponse™ Genetic Panel is specifically designed for clinicians managing complex neuropsychiatric conditions where standard approaches often fall short. By providing genetic insights into treatment response, we help you identify the optimal intervention pathway for each patient.
Treatment-Resistant Depression
Identify the neurobiological factors underlying treatment resistance and select the neuromodulation approach most likely to address the specific deficit.
Anxiety & PTSD
Determine whether a patient's anxiety presentation is more likely to respond to parasympathetic modulation (VNS) or cortical regulation (TMS).
Post-Concussion Syndrome
Assess genetic factors affecting neuroinflammation and neuroplasticity after brain injury to optimize neurorehabilitation strategies.
TMS & Neurostimulation Clinics
Reduce dropout rates and increase successful outcomes by matching patients to the optimal stimulation protocols from the start.
Any clinical practice that believes mental health treatment should be personalized rather than standardized will find our genetic panel transforms their approach to complex cases. The difference between guesswork and precision is often measured in months of patient suffering and thousands in wasted healthcare dollars.
Meet the panel supercharging your cure
We combine your genetic data with your real time physiologic response to decrease adverse events.
Building the Future of Mental Health—One Genome at a Time
At Electricogenetics, we're pioneering the convergence of genetics and neuromodulation to create a new standard in precision psychiatry. Our mission is to eliminate the trial-and-error approach that has dominated mental health treatment for too long.
"The integration of genetic testing into our neuromodulation practice has revolutionized our approach. We're seeing higher remission rates, faster responses, and significantly improved patient satisfaction." — Neuroscience Treatment Center of Manhattan
By providing clinicians with the genetic insights that matter most for treatment selection and protocol design, we're helping to ensure that every patient receives the intervention most likely to succeed for their unique neurobiological profile.
Join the growing community of forward-thinking clinicians who are transforming mental health care through personalized, genetically-informed neuromodulation. Your patients deserve nothing less than treatment designed specifically for their brain.